Skip to Content
Merck
CN

15429

Boc-Asp(OtBu)-OH

≥99.0% (sum of enantiomers, TLC)

Synonym(s):

Boc-L-aspartic acid 4-tert-butyl ester

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Linear Formula:
(CH3)3COCOCH2CH[NH(COOC(CH3)3]COOH
CAS Number:
1676-90-0
Molecular Weight:
289.32
UNSPSC Code:
12352209
NACRES:
NA.22
PubChem Substance ID:
57647421
MDL number:
MFCD00076912
Beilstein/REAXYS Number:
2336144

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Boc-Asp(OtBu)-OH, ≥99.0% (sum of enantiomers, TLC)

InChI

1S/C13H23NO6/c1-12(2,3)19-9(15)7-8(10(16)17)14-11(18)20-13(4,5)6/h8H,7H2,1-6H3,(H,14,18)(H,16,17)/t8-/m0/s1

SMILES string

CC(C)(C)OC(=O)C[C@H](NC(=O)OC(C)(C)C)C(O)=O

InChI key

PHJDCONJXLIIPW-QMMMGPOBSA-N

assay

≥99.0% (sum of enantiomers, TLC)

form

powder

optical activity

[α]20/D +2.0±0.4°, c = 1% in methanol

reaction suitability

reaction type: Boc solid-phase peptide synthesis

mp

64-67 °C

application(s)

peptide synthesis

storage temp.

2-8°C

Quality Level

100

Related Categories

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCK4518
BCCD1776
BCCC3867
BCBZ4952
BCBD7958V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Shugo Yamashita et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 157, 85-96 (2020-10-12)
Bone-drug targeting therapies using nanoparticles based on targeting ligands remain challenging due to their uptake clearance at non-target sites such as the liver, kidney, and spleen. Furthermore, the distribution sites of nanoparticles in bones have not been fully investigated, thus

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service